Takeda, a Japanese pharmaceutical giant, is cutting hundreds of jobs in Switzerland as part of its efforts to reduce costs in the face of rising inflation and growing pressure on drug prices. Despite renovating its headquarters in Opfikon with state-of-the-art technology and offering employees generous home office policies, the mood among the workforce remains depressed.
The pharmaceutical industry is facing significant challenges due to declining revenues and rising costs. In response, major companies like Pfizer and Novartis have announced job cuts to offset these challenges. While Switzerland offers advantages for these companies, there are concerns about maintaining access to skilled workers in Europe amid changing regulations.
Takeda’s headquarters in Opfikon has been completely renovated and equipped with the latest technology. The six-story office building houses around 1,200 employees from over 60 nations, not far from Zurich Airport. However, despite all the amenities available, including seating areas, coffee rooms and a newly designed canteen with several daily changing menus, the mood among the workforce remains depressed.
Takeda plans to eliminate one in ten jobs in Opfikon, which is where the company’s entire European business is managed. The consultation process with employees has been completed and 120 jobs will be lost. Those who are laid off will be given priority when vacant positions are filled, but the future remains uncertain.
